Anika Therapeutics (ANIK) 47.89 $ANIK Arena (ARNA)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2016 at 5:07 AM

Anika Therapeutics (ANIK) 47.89 $ANIK

Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.27 (+0.10), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), ARNA: 1.57 (+0.01)

Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)

Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:30AM CDT
Zacks.com featured highlights: SodaStream International, Children's Place, Quidel, MKS Instruments and Anika Therapeutics
PLCE: 83.00 (+0.09), QDEL: 21.58 (-0.16), MKSI: 49.60 (+0.35), ANIK: 47.89 (-0.05), SODA: 28.01 (+0.14)

Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)

Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)

Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)

Get Nice Earnings Surprise With These 5 Stocks
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:30AM CDT
Your search for tickers with the potential of positive earnings surprise ends here.
PLCE: 83.00 (+0.09), QDEL: 21.58 (-0.16), MKSI: 49.60 (+0.35), ANIK: 47.89 (-0.05), SODA: 28.01 (+0.14)

Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)

CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)

Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)

Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)

Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)

Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:38AM CDT
Keryx Biopharmaceuticals (KERX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
ANIK: 47.89 (-0.05), KERX: 4.15 (+0.02)

Illumina Keen on Genome Network Growth & Global Expansion
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 2:23PM CDT
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
HSKA: 52.49 (-0.27), ILMN: 167.90 (-0.66), ANIK: 47.89 (-0.05)

Vanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:30AM CDT
Vanda Pharmaceuticals, Inc. (VNDA) shares rose over 20% in the last trading session.
VNDA: 15.55 (+0.26), ANIK: 47.89 (-0.05)

Anika to Participate in Upcoming Investor Conferences
BusinessWire - Thu Aug 25, 3:05PM CDT
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"

technology, today announced that its Chief Financial Officer, Sylvia Cheung, will participate in the following upcoming investor conferences:
ANIK: 47.89 (-0.05)

Amgen Gets CRL for Secondary Hyperparathyroidism Drug
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:28AM CDT
Amgen (AMGN) announced that the FDA has issued a Complete Response Letter from for its New Drug Application (NDA) for Parsabiv.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)

Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)

Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:51AM CDT
Xenetic (XBIO) announced that the FDA has accepted the company's Investigational New Drug application to initiate a phase II study on Virexxa.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)

Portola IndexXa's Regulatory Application Validated in the EU
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:48AM CDT
Portola (PTLA) announced that the European Medicines Agency has accepted to review the company's Marketing Authorization Application for IndexXa.
PTLA: 21.03 (+0.17), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

ManuTech Center Set to Revolutionize Manufacturing Hub

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....